Literature DB >> 3280305

Hepatotoxic reactions associated with carbamazepine therapy.

S Horowitz1, R Patwardhan, E Marcus.   

Abstract

Hepatotoxic reactions in patients receiving carbamazepine (CBZ) therapy have been reported, and some have been considered fatal. We present two patients with hepatic dysfunction secondary to CBZ therapy. Liver biopsies were compatible with hepatotoxic damage, and the symptoms were reversible with medication withdrawal. Our patients are representative of those in the literature, most of whom have granulomatous hepatitis and sometimes have associated cholangitis. The patients with fatal reactions differed clinically and pathologically from the others, and may represent a different entity. The clinical syndrome resembles a viral hepatitis. Elderly patients seem to be particularly susceptible and their hepatic function should be monitored closely when CBZ therapy is initiated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280305     DOI: 10.1111/j.1528-1157.1988.tb04411.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Hepatorenal failure after carbamazepine therapy.

Authors:  N Hadzić
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

2.  Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.

Authors:  M Pirmohamed; A Graham; P Roberts; D Smith; D Chadwick; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

3.  Acute liver failure induced by carbamazepine.

Authors:  N Hadzić; B Portmann; E T Davies; A P Mowat; G Mieli-Vergani
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

4.  Hepatoprotective and antioxidant activity of N-acetyl cysteine in carbamazepine-administered rats.

Authors:  Eswaran Maheswari; Ganesan Raja Lekshmi Saraswathy; Thakur Santhranii
Journal:  Indian J Pharmacol       Date:  2014 Mar-Apr       Impact factor: 1.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.